ArticleFrontiers in medicine2026
Identification and longitudinal evaluation of inhaled medication adherence barriers using clinical natural language processing in asthma: a real-world cohort study.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: To develop a rule-enhanced clinical natural language processing (clinical NLP) framework for the automated identification of inhaled medication adherence barriers in asthma, characterize their longitudinal trajectories, and evaluate their associations with longitudinal medication adherence. Methods: This real-world longitudinal cohort study included patients with asthma receiving standardized management at a tertiary hospital. Free-text telephone follow-up records from three visits were analyzed using a rule-enhanced clinical NLP framework to identify five adherence barriers: intentional treatment discontinuation, concerns about side effects, medication access barriers, unintentional forgetfulness, and disease denial. Generalized estimating equations (GEE) were used to assess longitudinal associations between adherence barriers and high medication adherence. Complete-case analysis and Firth penalized logistic regression were performed as sensitivity analyses. Results: A total of 216 patients were included; evaluable adherence data were available for 209, 194, and 176 patients at Waves 1, 2, and 3, respectively. The primary GEE analysis included 579 observations from 216 patients. The NLP framework achieved an overall accuracy of 97.4% and an F1 score of 0.883. Intentional treatment discontinuation (OR = 0.143, 95% CI: 0.080-0.258), concerns about side effects (OR = 0.330, 95% CI: 0.163-0.666), and unintentional forgetfulness (OR = 0.059, 95% CI: 0.012-0.278) were associated with lower odds of high adherence. Medication access barriers and disease denial were not statistically significant. Intentional treatment discontinuation increased across follow-up waves, whereas concerns about side effects increased mainly at the final wave. The proportion of low adherence increased from 11.5% among patients without identified barriers to 68.8% among those with three or more barriers ( Conclusion: Rule-enhanced clinical NLP may help extract adherence-related information from routine asthma follow-up records. Intentional treatment discontinuation and unintentional forgetfulness were relatively consistent markers of low adherence, whereas findings for concerns about side effects require cautious interpretation. External validation in larger, multi-center populations is needed before broader clinical application.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.